NCT02222363 is a Phase 1 clinical trial of VLX600 in Refractory Cancer, sponsored by Vivolux AB.

Who is sponsoring NCT02222363?

NCT02222363 is sponsored by Vivolux AB.

What drugs are being tested in NCT02222363?

Interventions in NCT02222363: VLX600.

What condition does NCT02222363 study?

NCT02222363 studies Refractory Cancer.

Is NCT02222363 still recruiting?

NCT02222363 is currently terminated. Last updated 11 May 2018.

Last reviewed 2018-05-11 · How we verify

NCT02222363

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

Terminated Phase 1 Last updated 11 May 2018

What this trial tests

Phase 1 trial testing VLX600 in Refractory Cancer in 19 participants. Terminated before completion.

Timeline

18 February 2015

Primary endpoint
28 December 2016

28 December 2016

Quick facts

Lead sponsor	Vivolux AB
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	18 February 2015
Primary completion	28 December 2016
Estimated completion	28 December 2016
Sites	3 locations across United States

Drugs / interventions tested

VLX600 — full drug profile →

Conditions studied

Refractory Cancer — all drugs for Refractory Cancer →

Sponsor

Vivolux AB — full company profile →

Who can join

18 and older, any sex, with Refractory Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of the investigational drug VLX600 in patients with refractory advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Iron and Cancer.
Torti SV, Manz DH, Paul BT, Blanchette-Farra N, et al · · 2018 · cited 335× · PMID 30130469 · DOI 10.1146/annurev-nutr-082117-051732
Iron as a Central Player and Promising Target in Cancer Progression.
Jung M, Mertens C, Tomat E, Brüne B. · · 2019 · cited 195× · PMID 30641920 · DOI 10.3390/ijms20020273
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.
Jin P, Jiang J, Zhou L, Huang Z, et al · · 2022 · cited 180× · PMID 35851420 · DOI 10.1186/s13045-022-01313-4
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
Xu Y, Xue D, Bankhead A, Neamati N. · · 2020 · cited 127× · PMID 33103432 · DOI 10.1021/acs.jmedchem.0c01013
Iron chelators target both proliferating and quiescent cancer cells.
Fryknäs M, Zhang X, Bremberg U, Senkowski W, et al · · 2016 · cited 55× · PMID 27924826 · DOI 10.1038/srep38343
Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection.
Qiu X, Li Y, Zhang Z. · · 2023 · cited 37× · PMID 37040057 · DOI 10.1007/s13402-023-00801-0
Iron, inflammation and invasion of cancer cells.
Fischer-Fodor E, Miklasova N, Berindan-Neagoe I, Saha B. · · 2015 · cited 27× · PMID 26609256 · DOI 10.15386/cjmed-492
Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis.
Rademaker G, Costanza B, Bellier J, Herfs M, et al · · 2019 · cited 22× · PMID 30850580 · DOI 10.1038/s41389-019-0130-6

Verify or expand the search:

Other recruiting trials for Refractory Cancer

Currently open trials in the same condition.

NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
NCT06096038 — Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC · Phase 1, PHASE2 · recruiting
NCT06184035 — A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer · Phase 1, PHASE2 · recruiting
NCT05852717 — Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed · Phase 2 · recruiting
NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting

Other Vivolux AB trials

Trials by the same sponsor.

NCT02372240 — A Study of VLX1570 and Dexamethasone in Myeloma Patients · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02222363 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vivolux AB
Last refreshed: 11 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02222363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing